Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251714 · ClinicalTrials.gov registry record · Phase 1
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
A Phase 1 study of Breast Cancer and Advanced Solid Tumor, sponsored by Treadwell Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 4
- Study locations
NCT05251714 is a Phase 1 study of Breast Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Treadwell Therapeutics. The registered enrollment target is 44 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05251714, a Phase 1 study of Breast Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Treadwell Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG CFI-402257
Study Locations (4)
Ohio
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- START San Antonio - San Antonio
Utah
- START - Mountain Region - West Valley City
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05251714
The ClinicalTrials.gov registry entry for NCT05251714 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Treadwell Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT05251714 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT05251714 about?
NCT05251714 is a clinical study titled "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer". The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.
What is the current status of trial NCT05251714?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-05-27. Estimated completion is 2026-08.
What conditions does trial NCT05251714 study?
This clinical trial studies the following conditions: Breast Cancer, Advanced Solid Tumor.
What interventions are being tested in trial NCT05251714?
The interventions under investigation include: Fulvestrant (DRUG), CFI-402257 (DRUG).
Who is sponsoring clinical trial NCT05251714?
This trial is sponsored by Treadwell Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05251714 being conducted?
This trial has 4 study locations across Ohio, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.